Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of VX-272 in Healthy Subjects
NCT07437105Phase 1Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-272 in cystic fibrosis (CF) (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 66. Started Feb 2026; status: recruiting.
02
Drugs
VX-272
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07437105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437105.